Blog
RSS FeedPosted by Michael Wonder on 06 Sep 2018
Proposal on the funding of infliximab, rituximab and tocilizumab
6 September 2018 - PHARMAC is proposing to change how three hospital medicines are managed within the Pharmaceutical Schedule. ...
Posted by Michael Wonder on 29 Aug 2018
Proposal to move to one funded brand of lamotrigine (Logem)
29 August 2018 - PHARMAC is seeking feedback on a proposed change to the funding of lamotrigine dispersible tablets used ...
Posted by Michael Wonder on 27 Aug 2018
Battling cancer and fighting for funding
28 August 2018 - Dr Rosalie Stephens turns up to work these days with hope. ...
Posted by Michael Wonder on 21 Aug 2018
Proposal to change the funded brand of epoetin alfa
21 August 2018 - PHARMAC is seeking feedback on a proposed change to the funded brand of epoetin alfa [erythropoietin ...
Posted by Michael Wonder on 20 Aug 2018
Treatment funded in Australia, but New Zealand brother misses out
21 August 2018 - James McGoram says the genetic disease he has is yet to affect his day-to-day life but ...
Posted by Michael Wonder on 16 Jul 2018
PHARMAC work in funding medicines for rare disorders progressing
16 July 2018 - PHARMAC is progressing work aimed at improving funded access to medicines for rare disorders. ...
Posted by Michael Wonder on 02 Jul 2018
Another multi-product proposal from Novartis, this time involving ten pharmaceuticals
2 July 2018 - PHARMAC is seeking feedback on a proposal to fund five new treatments, widen access to three ...
Posted by Michael Wonder on 08 Jun 2018
Decision to fund denosumab for osteoporosis
8 June 2018 - PHARMAC is pleased to announce a decision to fund denosumab (Prolia) for the treatment of severe, ...
Posted by Michael Wonder on 17 May 2018
Budget 2018: PHARMAC to buy all medicines for DHBs
17 May 2018 - People who need expensive PHARMAC funded drugs can access them regardless of their DHB's ability to ...
Posted by Michael Wonder on 17 May 2018
PHARMAC budget 2018/19
17 May 2018 - PHARMAC is pleased that the Government has announced an uplift in PHARMAC’s funding. ...
Posted by Michael Wonder on 14 May 2018
Decision to widen access and change the funded brand of tenofovir disoproxil and entecavir
14 May 2018 - PHARMAC is pleased to announce decisions to approve agreements with Teva Pharma New Zealand Limited and ...
Posted by Michael Wonder on 08 May 2018
Notification of delay of decision on denosumab funding proposal
8 May 2018 - PHARMAC would like to advise all interested parties that there will be a delay in the ...
Posted by Michael Wonder on 15 Mar 2018
Proposal to fund denosumab for osteoporosis
16 March 2018 - PHARMAC is proposing to fund denosumab (Prolia) injections from 1 June 2018 for the treatment of severe, ...
Posted by Michael Wonder on 21 Feb 2018
Charity upset pre-election pledge for separate fund for rare diseases off the table
21 February 2018 - The country's biggest charity helping people dealing with rare disorders is upset the Government has gone ...
Posted by Michael Wonder on 15 Jan 2018
PHARMAC approves funding for treatment for 'mighty Mon'
14 January 2018 - A woman fighting cancer for the third time - and who was told she may only ...